Cyabra (CYAB) Director James Flanagan Buys Stock & Receives Warrants

What Happened

• James Flanagan, a director of Cyabra, Inc. (CYAB), reported a package of transactions on July 10, 2026 that reflect a private purchase of common stock and the acquisition of related warrants. The Form 4 lists three entries: an acquisition (A) of 114,940 shares at $0.43 (reported value $49,999) and two derivative purchases (P) of 114,940 shares each at $0.45 and $0.50 (reported values $51,723 and $57,470). These three reported items total about $159,192.
• The filing’s footnotes clarify the underlying deal: Flanagan purchased 53,650 common shares in a private placement at $0.435 per share and received Series A and Series B warrants (each covering up to 53,650 shares). The warrants become exercisable only after requisite stockholder approval; Series B warrants expire 12 months after initial exercise and Series A warrants expire five years after initial exercise. This is a purchase (insider acquiring securities), not a sale.

Key Details

• Transaction date: July 10, 2026; Form 4 filed July 13, 2026 (appears timely—within the usual 3-business-day window).
• Reported line items (from the Form 4):
  • A — 114,940 shares @ $0.43; reported value $49,999.
  • P — 114,940 shares (derivative) @ $0.45; reported value $51,723.
  • P — 114,940 shares (derivative) @ $0.50; reported value $57,470.
• Footnotes (key points):
  • F1: Purchased 53,650 common shares in a private placement at $0.435/share.
  • F2–F6: Purchased Series A and Series B warrants to buy up to 53,650 shares each; both warrants become exercisable only after stockholder approval. Series B expires 12 months after initial exercise; Series A expires five years after initial exercise.
• Shares owned after transaction: Not specified in the provided filing details.
• Filing timeliness: Filed July 13 for transactions on July 10 — appears timely (no late-filing flag provided).

Context

• The “derivative” entries are warrant purchases, not immediate exercises of options. They give the insider the right to buy additional shares in the future if and when shareholder approval is obtained and the warrants are exercised.
• Purchases by insiders (private placement + warrants) can be viewed as a form of insider accumulation, but the warrants are contingent on shareholder approval and have differing expiration windows, so their potential dilution and timing depend on future events.
• This transaction is an acquisition (purchase/award), not a sale — it increases the insider’s potential economic exposure to the company, subject to the warrant exercisability conditions.